AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Medical Equipment, Supplies & Distribution

Delayed Nasdaq 03:50:46 2024-03-28 pm EDT 5-day change 1st Jan Change
5.865 USD +2.89% Intraday chart for AngioDynamics, Inc. +6.25% -25.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AngioDynamics Sells Two Product Lines to Spectrum Vascular for up to $45 Million Cash; Shares Up in Pre-Bell Trading MT
Spectrum Vascular acquired PICC and Midline Product Portfolios from AngioDynamics, Inc. for $45 million. CI
Angiodynamics, Inc. Announces Board Changes CI
AngioDynamics Receives FDA Clearance for Auryon XL Radial Access Catheter MT
Angiodynamics Announces FDA 510(K) Clearance of Auryon Xl Radial Access Catheter to Treat Peripheral Arterial Disease CI
AngioDynamics, Inc. Announces Dennis Meteny to Retire as A Member of the Board of Directors, Member of the Compensation Committee and Chair of the Audit Committee, Effective January 31, 2024 CI
Transcript : AngioDynamics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:00 AM
Raymond James Adjusts Price Target on AngioDynamics to $10 From $12, Maintains Outperform Rating MT
HC Wainwright Adjusts Price Target on AngioDynamics to $18 From $20, Keeps Buy Rating MT
Sector Update: Health Care Stocks Retreat Late Afternoon MT
AngioDynamics Shares Fall After Q2 Swing to Adjusted Loss; Revenue Drops MT
Top MIdday Decliners MT
Transcript : AngioDynamics, Inc., Q2 2024 Earnings Call, Jan 05, 2024
AngioDynamics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023 CI
David D. Helsel to Leave AngioDynamics, Inc. as Senior Vice President of Global Operations and R&D, Effective January 12, 2024 CI
AngioDynamics, Inc. Announces Manufacturing Operations Restructuring CI
AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
North American Morning Briefing : Bond Yields Rise -2- DJ
AngioDynamics, Inc.(NasdaqGS:ANGO) dropped from S&P Healthcare Equipment Select Industry Index CI
AngioDynamics Completes Patient Enrollment in Device Trial for Pulmonary Embolism Treatment MT
AngioDynamics, Inc. Completes Patient Enrollment in Apex-Av Study Assessing Alphavac F1885 System in Treatment of Pulmonary Embolism CI
Raymond James Adjusts Price Target on AngioDynamics to $12 From $13, Keeps Outperform Rating MT
HC Wainwright Adjusts AngioDynamics' Price Target to $20 From $19, Keeps Buy Rating MT
Transcript : AngioDynamics, Inc., Q1 2024 Earnings Call, Oct 04, 2023
Earnings Flash (ANGO) ANGIODYNAMICS Posts Q1 Revenue $78.7M, vs. Street Est of $77.7M MT
Chart AngioDynamics, Inc.
More charts
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
5.7 USD
Average target price
14 USD
Spread / Average Target
+145.61%
Consensus
  1. Stock
  2. Equities
  3. Stock AngioDynamics, Inc. - Nasdaq
  4. News AngioDynamics, Inc.
  5. AngioDynamics : Canaccord Genuity Adjusts Price Target on AngioDynamics to $24 From $18, Maintains Hold Rating